Synthetic Genes was Twist Bioscience’s largest product and service line in fiscal 2025, bringing in $113.60M of $145.02M (78%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Synthetic Genes | $61.51M | $73.54M | $92.68M | $113.60M | |||||
| Ngs Tools | $99.31M | $123.71M | — | — | |||||
| Antibody Discovery | $24.17M | $23.17M | $20.33M | — | |||||
| Oligo Pools | $12.42M | $14.49M | $16.91M | $20.23M | |||||
| Dna Libraries | $6.15M | — | $13.93M | $11.18M | |||||
| Dna & Biopharma Libraries | — | — | — | — | |||||
| Total | $203.57M | $234.91M | $143.85M | $145.02M |
Twist Bioscience brought in $145.02M from its three product and service lines in fiscal 2025, the year ended September 30, 2025. That is less than the $161.48M it reports by information by industry sector., so these lines do not cover all of its revenue. Synthetic Genes was the largest at $113.60M (78.3%), ahead of Oligo Pools at $20.23M (14.0%) and Dna Libraries at $11.18M (7.7%).
Compared with fiscal 2024, Synthetic Genes grew fastest, up 22.6% to $113.60M, while Dna Libraries fell the most, down 19.7% to $11.18M. Some of that change comes from Twist Bioscience regrouping its lines.
Twist Bioscience stopped reporting Ngs Tools ($123.71M in fiscal 2023) and Antibody Discovery ($20.33M in fiscal 2024) as separate lines.
Industrial Chemicals/Materials was Twist Bioscience’s largest revenue line in fiscal 2025, bringing in $93.25M of $161.48M (58%).
| Information by industry sector. | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Healthcare | $106.36M | $137.15M | $168.96M | — | |||
| Industrial Chemicals/Materials | $57.94M | — | — | $93.25M | |||
| Academic Research | $37.10M | $45.85M | $58.45M | $65.86M | |||
| Food/Agriculture | $2.17M | $2.79M | $2.09M | $2.37M | |||
| Total | $203.57M | $185.79M | $229.50M | $161.48M |
Twist Bioscience brought in $161.48M from its three revenue lines in fiscal 2025, the year ended September 30, 2025. Twist Bioscience regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $229.50M. Industrial Chemicals/Materials was the largest at $93.25M (57.7%), ahead of Academic Research at $65.86M (40.8%) and Food/Agriculture at $2.37M (1.5%).
Twist Bioscience stopped reporting Healthcare as a separate revenue line after fiscal 2024, when it brought in $168.96M.
Americas was Twist Bioscience’s largest region in fiscal 2022, bringing in $122.47M of $203.57M (60%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|
| Americas | $36.93M | $59.16M | $77.91M | $122.47M | ||
| Emea | $14.69M | $25.82M | $44.12M | $62.08M | ||
| United States | — | — | — | — | ||
| Apac | $2.76M | $5.12M | $10.30M | $19.01M | ||
| Asia Pacific | — | — | — | — | ||
| North America | — | — | — | — | ||
| Total | $54.39M | $90.10M | $132.33M | $203.57M |
Twist Bioscience brought in $203.57M from its three regions in fiscal 2022, the year ended September 30, 2022. That was up 53.8% from $132.33M in fiscal 2021. Americas was the largest at $122.47M (60.2%), ahead of Emea at $62.08M (30.5%) and Apac at $19.01M (9.3%).
Compared with fiscal 2021, Apac grew fastest, up 84.6% to $19.01M. Every region above 2% of revenue grew. From fiscal 2019 to 2022, combined revenue from these regions grew from $54.39M to $203.57M, a compound annual growth rate of 55.3%. Americas' share of the total fell from 67.9% to 60.2%.
Twist Bioscience (TWST) reports its revenue by product and service, by information by industry sector. and by geography. In fiscal 2025, Synthetic Genes was its largest product and service line, bringing in $113.60M (78.3% of the total), followed by Oligo Pools at $20.23M (14.0%).
Synthetic Genes was Twist Bioscience's largest product and service line in fiscal 2025, bringing in $113.60M, or 78.3% of the $145.02M total across its three product and service lines.
Industrial Chemicals/Materials was Twist Bioscience's largest revenue line in fiscal 2025, bringing in $93.25M, or 57.7% of the $161.48M total across its three revenue lines.
Americas was Twist Bioscience's largest region in fiscal 2022, bringing in $122.47M, or 60.2% of the $203.57M total across its three regions.
Among Twist Bioscience's regions that make up at least 2% of revenue, Apac grew fastest in fiscal 2022, up 84.6% from $10.30M to $19.01M.
Every figure comes from Twist Bioscience's annual financial filings, as reported. Each line keeps the name Twist Bioscience gives it, and years follow its fiscal calendar.
Twist Bioscience's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.